F-STAR THERAPEUTICS

f-star-therapeutics-logo

F-Star Therapeutics is a biopharmaceutical company dedicated to developing novel bispecific antibody products that provide a significant improvement over the current standard of care. Given its strong patent position, it is the only biopharmaceutical company with the ability to create and develop Fcab:tm: antibody fragments, and bispecific antibodies, by modifying the constant region of an antibody. In particular, F-starโ€™s Modular Antibody Technology:tm: enables rapid discovery and development... of bispecific antibodies by introducing additional binding sites to the constant region of an antibody and offers unprecedented ease in the development and manufacturing of bispecific monoclonal antibodies. Using the Modular Antibody Technology, F-star generates bispecific antibodies (mAb2:tm:) that possess the favourable characteristics of traditional monoclonal antibodies, without the production challenges often associated with other antibody formats. F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured funding and support from leading VC investors: Aescap Venture, Atlas Venture, Novo Ventures and TVM Capital; as well as from renowned strategic corporate investors: Merck Serono Ventures, MP Healthcare Venture Management and SR One. In 2013, F-star established an asset-centric vehicle structure through the formation of F-star Alpha Ltd., which included out-licensing of FS102 from F-star to F-star Alpha Ltd. In October 2014 Bristol-Myers Squibb obtained an exclusive option to buy F-star Alpha. In addition the company has alliances with Boehringer Ingelheim and Merck Serono, each covering multiple targets. In 2011, F-star was selected by FierceBiotech as one of the Fierce 15 winners. F-star currently employs over 35 people at its research site in Cambridge, UK.

#People #Financial #Event #Website #More

F-STAR THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Pharmaceutical

Founded:
2006-01-01

Address:
Cambridge, Cambridgeshire, United Kingdom

Country:
United Kingdom

Website Url:
http://www.f-star.com

Total Employee:
51+

Status:
Active

Contact:
+43 (0)-72055-4215

Email Addresses:
[email protected]

Total Funding:
137.29 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Domain Not Resolving Wordpress Plugins Nginx Sitelinks Search Box



Current Advisors List

david-a-arkowitz_image

David A. Arkowitz Board Member and Chair of Audit Committee @ F-Star Therapeutics
Board_member
2020-11-01

florian-ruker_image

Florian Ruker Scientific Advisors @ F-Star Therapeutics
Advisor

jean-francois-formela_image

Jean-Francois Formela Member of the Board of Directors @ F-Star Therapeutics
Board_member
2006-12-21

roel-bulthuis_image

Roel Bulthuis Board Member @ F-Star Therapeutics
Board_member

axel-polack_image

Axel Polack Board Director @ F-Star Therapeutics
Board_member
2011-01-01

Current Employees Featured

james-sandy_image

James Sandy
James Sandy Chief Development Officer @ F-Star Therapeutics
Chief Development Officer
2022-03-01

eliot-forster_image

Eliot Forster
Eliot Forster CEO @ F-Star Therapeutics
CEO
2018-10-01

darlene-deptula-hicks_image

Darlene Deptula-Hicks
Darlene Deptula-Hicks Chief Financial Officer @ F-Star Therapeutics
Chief Financial Officer
2019-05-01

florian-ruker_image

Florian Ruker
Florian Ruker Co-Founder @ F-Star Therapeutics
Co-Founder

not_available_image

Jane Dancer
Jane Dancer coo @ F-Star Therapeutics
coo

Founder


florian-ruker_image

Florian Ruker

Stock Details


Company's stock symbol is NASDAQ:FSTX

Acquisitions List

Date Company Article Price
2020-11-20 Spring Bank Pharmaceuticals Spring Bank Pharmaceuticals acquired by F-Star Therapeutics 30 M USD

Investors List

aescap-venture_image

Aescap Venture

Aescap Venture investment in Post-IPO Equity - F-Star Therapeutics

atlas-venture_image

Atlas Venture

Atlas Venture investment in Post-IPO Equity - F-Star Therapeutics

sr-one_image

SR One

SR One investment in Post-IPO Equity - F-Star Therapeutics

merckventures_image

M Ventures

M Ventures investment in Post-IPO Equity - F-Star Therapeutics

merckventures_image

M Ventures

M Ventures investment in Series A - F-Star Therapeutics

aescap-venture_image

Aescap Venture

Aescap Venture investment in Series A - F-Star Therapeutics

mp-healthcare-venture-management-inc_image

MP Healthcare Venture Management

MP Healthcare Venture Management investment in Series A - F-Star Therapeutics

sr-one_image

SR One

SR One investment in Series A - F-Star Therapeutics

atlas-venture_image

Atlas Venture

Atlas Venture investment in Series A - F-Star Therapeutics

tvm-capital_image

TVM Capital

TVM Capital investment in Series A - F-Star Therapeutics

Key Employee Changes

Date New article
2022-03-01 F-star Therapeutics Appoints James Sandy as Chief Development Officer

Official Site Inspections

http://www.f-star.com Semrush global rank: 4.61 M Semrush visits lastest month: 2.2 K

  • Host name: 160.89.214.35.bc.googleusercontent.com
  • IP address: 35.214.89.160
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "F-Star Therapeutics"

F-star - Wikipedia

F-star Biotechnology Ltd. is a biotechnology company, founded in Vienna in 2006, [1] with a current main research site in Cambridge, UK.The company is focused in developing bispecific โ€ฆSee details»

Home - F-star Therapeutics Inc.

F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.See details»

F-star Company Profile | Management and Employees List

F-star Profile and History F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a transformation in cancer therapy. By developing โ€ฆSee details»

About - F-star Therapeutics Inc.

Pharmaceutical Partnerships. F-starโ€™s platform has been validated through partnerships for over a decade. We have collaboration and licensing agreements with many leading biopharma companies to research, develop, and โ€ฆSee details»

F-Star Therapeutics - Crunchbase Company Profile

F-star is now applying its proprietary technology to the development of a pipeline of product candidates. Since its founding in 2006 the company has secured โ€ฆSee details»

Sarah Batey - F-star Therapeutics Inc.

I lead the portfolio and project management group at F-star, this involves working with many different teams across the organization to ensure that the projects and pipeline are delivered โ€ฆSee details»

F-star, an invoX company - Crunchbase

Organization. F-star, an invoX company . Connect to CRM . Save . Summary. People. Technology. Signals & News. ... Find More Contacts for F-star, an invoX company. Protected โ€ฆSee details»

F-star - Overview, News & Similar companies | ZoomInfo.com

Mar 6, 2023 F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a transformation in cancer therapy. By develo ping medicines that โ€ฆSee details»

F-Star Therapeutics - Funding, Financials, Valuation & Investors

F-Star Therapeutics is registered under the ticker NASDAQ:FSTX . F-Star Therapeutics is funded by 8 investors. Aescap Venture and Atlas Venture are the most recent investors. F-Star โ€ฆSee details»

F-star - Products, Competitors, Financials, Employees, โ€ฆ

F-star. Frequently Asked Questions (FAQ) When was F-star founded? F-star was founded in 2002. Where is F-star's headquarters? F-star's headquarters is located at Eddeva B920, โ€ฆSee details»

f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.

Organization type RDM biotech/pharma Region Vienna Cluster LISAvienna Focus human health Details. ENSEMO GmbH. Organization type RDM biotech/pharma Region Lower Austria โ€ฆSee details»

Spring Bank Pharmaceuticals and F-star Therapeutics Agree to โ€ฆ

Jul 29, 2020 Mintz Levin and Mills & Reeve are serving as legal counsel to F-star.Management and Organization Effective as of the closing of the transaction, Eliot Forster, Ph.D., MBA, will โ€ฆSee details»

F Star - Crunchbase Company Profile & Funding

Organization. F Star . Connect to CRM . Save . Summary. People. Signals & News. About. ... F Star provides IT consulting, system planning and introduction support from the standpoint of โ€ฆSee details»

What is F-Star? Company Culture, Mission, Values | Glassdoor

See what employees say it's like to work at F-Star. Salaries, reviews, and more - all posted by employees working at F-Star.See details»

F-star Therapeutics Reports Full-Year 2020 Financial Results and ...

F-star is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumor โ€ฆSee details»

Street Transvestite Action Revolutionaries - Wikipedia

Street Transvestite Action Revolutionaries (STAR) was a gay, gender non-conforming, and transvestite street activist organization founded in 1970 by Sylvia Rivera and Marsha P. โ€ฆSee details»

F Star - Contacts, Employees, Board Members, Advisors & Alumni

F Star provides IT consulting, system planning and introduction support from the standpoint of financial institutions and customers. Search Crunchbase. Start Free Trial . Chrome Extension. โ€ฆSee details»

Careers - F-star Therapeutics Inc.

EOE Statement: F-star is an Equal Opportunity Employer. By embracing diverse skills, perspectives, and ideas, we choose to lead. All qualified applicants will receive consideration โ€ฆSee details»

Jฤnis Timma, Former NBA Hopeful, Dead At 32 - HuffPost

3 days ago Latvian basketball player Jฤnis Timma, who was previously a member of the Orlando Magicโ€™s minor league organization, was found dead Tuesday at age 32. Gary Bassing via โ€ฆSee details»

Press Releases - F-star Therapeutics Inc.

Aug 4, 2022 F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022 » Mar 1, 2022 F-star Therapeutics Appoints James Sandy โ€ฆSee details»

linkstock.net © 2022. All rights reserved